Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKN1 | Q16512 | 3/20 | 0.52 |
| ▸ | PAK4 | O96013 | 2/20 | 0.52 |
| ▸ | WEE1 | P30291 | 4/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 6/20 | 0.46 |
| ▸ | PAK1 | Q13153 | 3/20 | 0.45 |
| ▸ | PAK3 | O75914 | 2/20 | 0.45 |
| ▸ | PAK2 | Q13177 | 2/20 | 0.45 |
| ▸ | SRC | P12931 | 4/20 | 0.43 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.43 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.43 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | KIT | P10721 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | TNK2 | Q07912 | 5/20 | 0.41 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.40 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13553736 | 0.86 | PKN1 (0.51) | PKN1PAK4WEE1FGFR1PAK1 | |
| SCHEMBL15785227 | 0.80 | PKN1 (0.44) | PKN1PAK4WEE1FGFR1PAK1 | |
| SCHEMBL15785380 | 0.79 | PAK4 (0.49) | PKN1PAK4PAK1TNK2 | |
| SCHEMBL15787960 | 0.76 | PKN1 (0.51) | PKN1PAK4WEE1FGFR1PAK1 | |
| SCHEMBL15036054 | 0.74 | PKN1 (0.45) | PKN1PAK4WEE1PAK1PAK3 | |
| SCHEMBL15785222 | 0.74 | TNK2 (0.44) | PKN1PAK4TNK2 | |
| SCHEMBL13553931 | 0.73 | PKN1 (0.43) | PKN1PAK4PAK1PAK3PAK2 | |
| SCHEMBL13553861 | 0.73 | PAK1 (0.49) | PKN1PAK4WEE1PAK1PAK3 | |
| SCHEMBL15787981 | 0.72 | PKN1 (0.41) | PKN1PAK4WEE1FGFR1PAK1 | |
| SCHEMBL15041264 | 0.72 | WEE1 (0.41) | PKN1PAK4WEE1FGFR1PAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | PKN1 326/4885PAK4 5/4885WEE1 545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.